Sphera Funds Management LTD. lifted its stake in shares of Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) by 18.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 110,033 shares of the company’s stock after purchasing an additional 17,002 shares during the quarter. Sphera Funds Management LTD. owned about 0.29% of Deciphera Pharmaceuticals worth $4,260,000 at the end of the most recent quarter.
Several other institutional investors also recently added to or reduced their stakes in DCPH. Citadel Advisors LLC increased its holdings in shares of Deciphera Pharmaceuticals by 1,048.3% in the 3rd quarter. Citadel Advisors LLC now owns 315,462 shares of the company’s stock valued at $12,215,000 after acquiring an additional 287,991 shares during the last quarter. BlackRock Inc. boosted its position in Deciphera Pharmaceuticals by 14.3% during the 3rd quarter. BlackRock Inc. now owns 675,818 shares of the company’s stock valued at $26,167,000 after purchasing an additional 84,754 shares during the period. Fosun International Ltd acquired a new position in Deciphera Pharmaceuticals during the 3rd quarter valued at approximately $4,958,000. Bank of New York Mellon Corp boosted its position in Deciphera Pharmaceuticals by 17.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 66,408 shares of the company’s stock valued at $2,571,000 after purchasing an additional 9,966 shares during the period. Finally, Janus Henderson Group PLC boosted its position in Deciphera Pharmaceuticals by 21.6% during the 3rd quarter. Janus Henderson Group PLC now owns 679,498 shares of the company’s stock valued at $26,310,000 after purchasing an additional 120,683 shares during the period. Institutional investors and hedge funds own 55.04% of the company’s stock.
Shares of DCPH stock opened at $27.96 on Friday. The company has a quick ratio of 18.46, a current ratio of 18.46 and a debt-to-equity ratio of 0.06. Deciphera Pharmaceuticals Inc has a 1 year low of $15.15 and a 1 year high of $45.61. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of -9.35 and a beta of 3.96.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings results on Thursday, November 8th. The company reported ($0.65) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.65). Equities analysts expect that Deciphera Pharmaceuticals Inc will post -2.65 EPS for the current year.
A number of research analysts recently issued reports on the company. BidaskClub upgraded Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 1st. Leerink Swann reduced their price objective on Deciphera Pharmaceuticals from $28.00 to $20.00 and set an “underperform” rating for the company in a research report on Friday, November 16th. Zacks Investment Research upgraded Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 price objective for the company in a research report on Tuesday, November 13th. Cantor Fitzgerald restated a “buy” rating and set a $53.00 price objective on shares of Deciphera Pharmaceuticals in a research report on Wednesday, October 3rd. Finally, ValuEngine upgraded Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, October 2nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company’s stock. Deciphera Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $43.11.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.
Read More: Swap
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.